•  
  •  
 

Bulletin of Chinese Academy of Sciences (Chinese Version)

Keywords

human embryo-derived cells, embryonic stem cells, ethics, regulation

Document Type

S & T and Society

Abstract

Since the establishment of the first human diploid cell line derived from aborted fetal tissue in the 1960s, human embryoderived cells have been widely used in biomedical field and significantly contributes to improving human health. In recent years, human pluripotent stem cells, including human embryonic stem cells (hESCs), have shown great therapeutic potential in regenerative medicine, and thus received great attention from governments and the public. However, due to various factors such as history, culture, religious beliefs, ethics and morality, research and application involving human embryo-derived cells have been controversial worldwide. This study explores the history and progress of human embryo-derived cells in the field of biomedicine, and analyzes the evolution of regulatory systems in different countries, with the aim of facilitating the improvement of China’s regulatory framework and technical requirements in this field.

First page

388

Last Page

396

Language

Chinese

Publisher

Bulletin of Chinese Academy of Sciences

References

1 Wood D J, Minor P D. Use of human diploid cells in vaccine production. Biologicals, 1990, 18(2):143-146.

2 Ghaderi D, Taylor R E, Padler-Karavani V, et al. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nature Biotechnology, 2010, 28(8):863-867.

3 World Medical Association. World medical association declaration of helsinki:Ethical principles for medical research involving human subjects. JAMA, 2013, 310(20):2191-2194.

4 Laurent A, Abdel-Sayed P, Hirt-Burri N, et al. Evolution of diploid progenitor lung cell applications:From optimized biotechnological substrates to potential active pharmaceutical ingredients in respiratory tract regenerative medicine. Cells, 2021, 10(10):2526.

5 Fletcher M A, Hessel L, Plotkin S A. Human diploid cell strains (HDCS) viral vaccines. Developments in Biological Standardization, 1998, 93:97-107.

6 Hayflick L. A brief history of cell substrates used for the preparation of human biologicals. Developments in Biologicals, 2001, 106:5-23.

7 Chanock R M, Ludwig W, Heubner R J, et al. Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. JAMA, 1966, 195(6):445-452.

8 Wadman M. The Vaccine Race:Science, Politics, and the Human Costs of Defeating Disease. New York:Viking, 2017.

9 Olshansky S J, Hayflick L. The role of the WI-38 cell strain in saving lives and reducing morbidity. AIMS Public Health, 2017, 4(2):127-138.

10 Jacobs J P, Jones C M, Baille J P. Characteristics of a human diploid cell designated MRC-5. Nature, 1970, 227:168-170.

11 Friedman H M, Koropchak C. Comparison of WI-38, MRC-5, and IMR-90 cell strains for isolation of viruses from clinical specimens. Journal of Clinical Microbiology, 1978, 7(4):368-371.

12 Jacobs J P, Garrett A J, Merton R. Characteristics of a serially propagated human diploid cell designated MRC-9. Journal of Biological Standardization, 1979, 7(2):113-122.

13 胡昭烈.人二倍体细胞2BS株小儿麻痹活疫苗Ⅰ型安全性和免疫原性观察.医学研究通讯, 1978, 11:26-30. Hu Z L. Observation on safety and immunogenicity of live polio vaccine type I of human diploid cell strain 2BS. Journal of Medical Research, 1978, 7(11):26-30.(in Chinese)

14 郭仁,曹逸云,代振洲,等.人二倍体细胞株KMB-17的特性.中国医学科学院学报, 1981, 3(4):226-230. Guo R, Cao Y Y, Dai Z Z, et al. Characteristics of a human diploid cell strain KMB-17. Acta Academiae Medicinae Sinicae, 1981, 3(4):226-230.(in Chinese)

15 宋彩花,任芳芳,刘杰,等.人用疫苗生产用人二倍体细胞株KMB17的鉴定.中国生物制品学杂志, 2018, 31(10):1135-1141. Song C H, Ren F F, Liu J, et al. Identification of human diploid cell KMB17 strain for production of vaccines for human use. Chinese Journal of Biologicals, 2018, 31(10):1135-1141.(in Chinese)

16 国家药典委员会.中华人民共和国药典(2020年版):三部.北京:中国医药科技出版社, 2020. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China 2020:Part III. Beijing:China Medical Science and Technology Press, 2020.(in Chinese)

17 Ma B, He L F, Zhang Y L, et al. Characteristics and viral propagation properties of a new human diploid cell line, Walvax-2, and its suitability as a candidate cell substrate for vaccine production. Human Vaccines&Immunotherapeutics, 2015, 11(4):998-1009.

18 Graham F L, Smiley J, Russell W C, et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. The Journal of General Virology, 1977, 36(1):59-74.

19 Lin Y C, Boone M, Meuris L, et al. Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nature Communications, 2014, 5:4767.

20 Dumont J, Euwart D, Mei B S, et al. Human cell lines for biopharmaceutical manufacturing:History, status, and future perspectives. Critical Reviews in Biotechnology, 2016, 36(6):1110-1122.

21 Rodrigues A F, Soares H R, Guerreiro M R, et al. Viral vaccines and their manufacturing cell substrates:New trends and designs in modern vaccinology. Biotechnology Journal, 2015, 10(9):1329-1344.

22 Tan E, Chin C S H, Lim Z F S, et al. HEK293 cell line as a platform to produce recombinant proteins and viral vectors. Frontiers in Bioengineering and Biotechnology, 2021, 9:796991.

23 Wu C Y, Cheng C W, Kung C C, et al. Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine. PNAS, 2022, 119(9):e2119995119.

24 Xie L Z, Metallo C, Warren J, et al. Large-scale propagation of a replication-defective adenovirus vector in stirred-tank bioreactor PER. C6TM cell culture under sparging conditions. Biotechnology and Bioengineering, 2003, 83(1):45-52.

25 Fallaux F J, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Human Gene Therapy, 1998, 9(13):1909-1917.

26 Thomson J A, Itskovitz-Eldor J, Shapiro S S, et al. Embryonic stem cell lines derived from human blastocysts. Science, 1998, 282:1145-1147.

27 Amit M, Carpenter M K, Inokuma M S, et al. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Developmental Biology, 2000, 227(2):271-278.

28 Umezawa A, Sato Y, Kusakawa S, et al. Research and development strategy for future embryonic stem cell-based therapy in Japan. JMA Journal, 2020, 3(4):287-294.

29 Stacey G N, Hao J. Biobanking of human pluripotent stem cells in China. Cell Proliferation, 2022, 55(7):e13180.

30 祝贺,郝捷,周琪,等.临床级干细胞库及干细胞制剂.生命科学, 2016, 28(8):895-901. Zhu H, Hao J, Zhou Q, et al. Clinical-grade stem cell bank and stem cell products. Chinese Bulletin of Life Sciences, 2016, 28(8):895-901.(in Chinese)

31 Schwartz S D, Regillo C D, Lam B L, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy:follow-up of two open-label phase 1/2 studies. The Lancet, 2015, 385:509-516.

32 Ramzy A, Thompson D M, Ward-Hartstonge K A, et al. Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell, 2021, 28(12):2047-2061.e5.

33 Menasché P, Vanneaux V, Hagège A, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment:First clinical case report. European Heart Journal, 2015, 36(30):2011-2017.

34 Deinsberger J, Reisinger D, Weber B. Global trends in clinical trials involving pluripotent stem cells:A systematic multi-database analysis. NPJ Regenerative Medicine, 2020, 5:15.

35 Laurent A, Rey M, Scaletta C, et al. Retrospectives on three decades of safe clinical experience with allogeneic dermal progenitor fibroblasts:High versatility in topical cytotherapeutic care. Pharmaceutics, 2023, 15(1):184.

36 Hohlfeld J, de Buys Roessingh A, Hirt-Burri N, et al. Tissue engineered fetal skin constructs for paediatric burns. The Lancet, 2005, 366:840-842.

37 Wadman M. Medical research:Cell division. Nature, 2013, 498:422-426.

38 Guidelines for the Conduct of Human Embryonic Stem Cell Research. Current Protocols in Stem Cell Biology, 2009, 9(1):A.1A.1.

39 Lovell-Badge R, Anthony E, Barker R A, et al. ISSCR guidelines for stem cell research and clinical translation:The[2021] update. Stem Cell Reports, 2021, 16(6):1398-1408.

40 Simonstein F. Embryonic stem cells:the disagreement debate and embryonic stem cell research in Israel. Journal of Medical Ethics, 2008, 34(10):732-734.

41 European Parliament. Directive 2004/23/EC of the European Parliament and of the Council.(2004-03-31)[2022-12-30]. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02004L0023-20090807.

42 Butler D. France mulls embryo research reform. Nature, 2011, 469:277-277.

43 Drabiak-Syed B K. New president, new human embryonic stem cell research policy:Comparative international perspectives and embryonic stem cell research laws in France. Biotechnology Law Report, 2013, 32(6):349-356.

44 张业亮.美国围绕胚胎干细胞研究的道德和政治争议.美国研究, 2013, 27(3):62-88. Zhang Y L. Moral and political controversy on embryonic stem cell research in America. The Chinese Journal of American Studies, 2013, 27(3):62-88.(in Chinese)

45 Williams D A. National Institutes of Health releases new guidelines on human stem cell research. Molecular Therapy:the Journal of the American Society of Gene Therapy, 2009, 17(9):1485-1486.

46 Fink Jr D W. FDA regulation of stem cell-based products. Science, 2009, 324:1662-1663.

47 Food and Drug Administration. Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products. Final rule. Federal Register, 2004, 69(101):29785-29834.

48 European Medicine Agency. Reflection Paper on Stem CellBased Medicinal Products. London:EMA, 2011.

49 Lovell-Badge R. The regulation of human embryo and stemcell research in the United Kingdom. Nature Reviews Molecular Cell Biology, 2008, 9(12):998-1003.

50 Mizuno H. Ethical Issues for Clinical Studies That use Human Embryonic Stem Cells:The 2014 Revisions to the Japanese Guidelines. Stem Cell Reviews and Reports, 2015, 11(5):676-680.

51 Hayakawa T, Aoi T, Umezawa A, et al. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of human embryonic stem cells. Regenerative Therapy, 2015, 2:109-122.

52 Peng Y J, Huang X, Zhou Q. Ethical and policy considerations for human embryo and stem cell research in China. Cell Stem Cell, 2020, 27(4):511-514.

Download
Request a Copy

Share

COinS